Treatment cost of narcolepsy with cataplexy in the Central Europe
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F62690094%3A18470%2F16%3A50005042" target="_blank" >RIV/62690094:18470/16:50005042 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/62690094:18450/16:50005042
Výsledek na webu
<a href="http://dx.doi.org/10.2147/TCRM.S119888" target="_blank" >http://dx.doi.org/10.2147/TCRM.S119888</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.2147/TCRM.S119888" target="_blank" >10.2147/TCRM.S119888</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Treatment cost of narcolepsy with cataplexy in the Central Europe
Popis výsledku v původním jazyce
Introduction Narcolepsy is a lifelong rare neurological sleep disorder characterized by chronic, excessive attacks of day-time sleepiness. This disease is often extremely incapacitating, interfering with every aspect of life, in work and social settings. Objective The purpose of this study is to specify the treatment costs of patients in central Europe (Czech Republic), while the main attention is paid to the drugs that are fully or partially covered by public health insurance. Furthermore, concomitant therapy is also evaluated since it represents a certain financial burden for patients and their family members. On the basis of the calculated costs, impact on the public budget is evaluated. Research design and methods This study monitors the direct costs of the drugs for the 13 patients, which represents their total number in the Czech Republic and evaluates the costs of their treatment in the period of 9.1.2011 - 23.4.2013. Results Most of the treatment costs were covered from publically available sources (about 80 %). This conclusion is also true for the concomitant therapy of comorbidities. The additional payments of drugs are about 20% of the total costs.
Název v anglickém jazyce
Treatment cost of narcolepsy with cataplexy in the Central Europe
Popis výsledku anglicky
Introduction Narcolepsy is a lifelong rare neurological sleep disorder characterized by chronic, excessive attacks of day-time sleepiness. This disease is often extremely incapacitating, interfering with every aspect of life, in work and social settings. Objective The purpose of this study is to specify the treatment costs of patients in central Europe (Czech Republic), while the main attention is paid to the drugs that are fully or partially covered by public health insurance. Furthermore, concomitant therapy is also evaluated since it represents a certain financial burden for patients and their family members. On the basis of the calculated costs, impact on the public budget is evaluated. Research design and methods This study monitors the direct costs of the drugs for the 13 patients, which represents their total number in the Czech Republic and evaluates the costs of their treatment in the period of 9.1.2011 - 23.4.2013. Results Most of the treatment costs were covered from publically available sources (about 80 %). This conclusion is also true for the concomitant therapy of comorbidities. The additional payments of drugs are about 20% of the total costs.
Klasifikace
Druh
J<sub>x</sub> - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
CEP obor
FQ - Veřejné zdravotnictví, sociální lékařství
OECD FORD obor
—
Návaznosti výsledku
Projekt
—
Návaznosti
S - Specificky vyzkum na vysokych skolach
Ostatní
Rok uplatnění
2016
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Therapeutics and clinical risk management
ISSN
1178-203X
e-ISSN
—
Svazek periodika
12
Číslo periodika v rámci svazku
11/2016
Stát vydavatele periodika
NZ - Nový Zéland
Počet stran výsledku
7
Strana od-do
1709-1715
Kód UT WoS článku
000388021300001
EID výsledku v databázi Scopus
—